Title
Category
Credits
Event date
Cost
Addressing Patients’ Unmet Needs to Improve Outcomes in Schizophrenia
  • Adherence
  • Antipsychotics
  • Delivery of Care
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
What are some of the challenges you face in overcoming adherence issues and providing patient-centered care for people living with schizophrenia? Drs Harvey and Kane offer evidence and clinical experience on these topics in this journal CME activity.
Diagnosis and Pharmacotherapy of Bipolar Depression in Pediatric Patients
  • Bipolar Disorder
  • Depression
  • Child and Adolescent Psychiatry
  • Diagnostic Tools
  • Psychopharmacology
  • Side Effects
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
What are the evidence-based pharmacologic treatment approaches for pediatric patients with bipolar depression?
Diagnosis and Pharmacotherapy of Bipolar Depression in Adults
  • Bipolar Disorder
  • Depression
  • Diagnostic Tools
  • Psychopharmacology
  • Side Effects
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Join Dr Goldberg as he reviews factors that impact the diagnosis of bipolar disorder and current treatments for bipolar depression in adults.
Treatment-Resistant Schizophrenia: Definition, Predictors, and Therapy Options
  • Antipsychotics
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • Treatment Resistance
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Two experts offer a refresher on predictors and identification of treatment-resistant schizophrenia. Drs Correll and Howes also review therapeutic strategies.
Improving Standards of Care in Type 2 Diabetes with Chronic Kidney Disease: Integrating the Non-Steroidal Mineralocorticoid Antagonist Class in Cardiorenal Medicine
  • Renal Disease
  • Primary Care
  • Patient/Physician Communication
  • Side Effects
  • Cardiology
  • Metabolic Disorders
  • Diagnostic Tools
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
How to screen UACR and eGFR levels, implement selective non-steroidal MRA therapies, and mitigate the risk of hyperkalemia to prevent CKD disease progression
Managing the Physical, Neuropsychiatric, and Cognitive Health Needs of Patients With Duchenne Muscular Dystrophy
  • Sleep
  • Depression
  • Attention-Deficit/Hyperactivity Disorder
  • Child and Adolescent Psychiatry
  • Cognition
  • Delivery of Care
  • Diagnostic Tools
  • Muscular Dystrophy
  • Obsessive-Compulsive and Related Disorders
  • Patient/Physician Communication
  • Psychopharmacology
  • Side Effects
  • Violence/Aggression
  • Weight
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
This video reviews treatment guidelines for patients with DMD and emphasizes the importance of clinicians intervening early on behalf of individuals who develop behavioral-psychosocial comorbidities.
Tardive Dyskinesia: Subtle Symptoms and the Huge Impact of Early Recognition and Intervention
  • Movement Disorders
  • Psychotic Disorders
  • Side Effects
  • Tardive Dyskinesia
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Clinicians should screen regularly for signs and symptoms of tardive dyskinesia and educate patients and caregivers on what to look for and report, leading to earlier intervention and better quality of life.
Translating Clinical Trial Data into Real-World Practice: Examining CKD Screening and Three Patient Case Profiles
  • Renal Disease
  • Adherence
  • Cardiology
  • Comorbidity
  • Diagnostic Tools
  • Education
  • Medical Conditions
  • Primary Care
  • Side Effects
  • Weight
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Regular screening of UACR and adding finerenone to SGLT2 inhibitors can greatly impact T2D at risk for CKD. Join faculty as they discuss three patient cases.